CL2020000085A1 - Moduladores de nlrp3. - Google Patents

Moduladores de nlrp3.

Info

Publication number
CL2020000085A1
CL2020000085A1 CL2020000085A CL2020000085A CL2020000085A1 CL 2020000085 A1 CL2020000085 A1 CL 2020000085A1 CL 2020000085 A CL2020000085 A CL 2020000085A CL 2020000085 A CL2020000085 A CL 2020000085A CL 2020000085 A1 CL2020000085 A1 CL 2020000085A1
Authority
CL
Chile
Prior art keywords
nlrp3
modulators
nlrp3 modulators
compounds
medicines
Prior art date
Application number
CL2020000085A
Other languages
English (en)
Inventor
O'malley Daniel
V Gavai Ashvinikumar
Gill Patrice
M Tarby Christine
Hunter Watterson Scott
Gong Hua
K Williams David
Ghosh Shomir
R Roush William
Original Assignee
Innate Tumor Immunity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63036509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020000085(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innate Tumor Immunity Inc filed Critical Innate Tumor Immunity Inc
Publication of CL2020000085A1 publication Critical patent/CL2020000085A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Amplifiers (AREA)
  • Burglar Alarm Systems (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS DE LA FÓRMULA (I), EN DONDE TODAS LAS VARIABLES SON COMO SE DEFINEN EN LA PRESENTE. ESTOS COMPUESTOS SON MODULADORES DE NLRP3, QUE SE PUEDEN UTILIZAR COMO MEDICAMENTOS PARA EL TRATAMIENTO CONTRA TRASTORNOS PROLIFERATIVOS, TALES COMO CÁNCER EN UN SUJETO (POR EJEMPLO, UN SER HUMANO).
CL2020000085A 2017-07-14 2020-01-10 Moduladores de nlrp3. CL2020000085A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762532932P 2017-07-14 2017-07-14
US201862662405P 2018-04-25 2018-04-25
US201862689412P 2018-06-25 2018-06-25

Publications (1)

Publication Number Publication Date
CL2020000085A1 true CL2020000085A1 (es) 2020-07-10

Family

ID=63036509

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000085A CL2020000085A1 (es) 2017-07-14 2020-01-10 Moduladores de nlrp3.

Country Status (18)

Country Link
US (2) US11344543B2 (es)
EP (1) EP3652166B1 (es)
JP (1) JP7159282B2 (es)
KR (1) KR102698385B1 (es)
CN (2) CN111793060B (es)
AU (1) AU2018301681B2 (es)
BR (1) BR112020000523A2 (es)
CA (1) CA3069524A1 (es)
CL (1) CL2020000085A1 (es)
CO (1) CO2020000227A2 (es)
ES (1) ES3002968T3 (es)
IL (1) IL271935A (es)
MY (1) MY201080A (es)
NZ (1) NZ761519A (es)
PE (1) PE20200296A1 (es)
SG (1) SG11202000248UA (es)
TW (1) TWI791556B (es)
WO (1) WO2019014402A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7351850B2 (ja) 2018-04-25 2023-09-27 イネイト・テューマー・イミュニティ・インコーポレイテッド Ｎｌｒｐ３修飾因子
KR102865929B1 (ko) * 2019-01-14 2025-09-29 인네이트 튜머 이뮤니티, 인코포레이티드 Nlrp3 조정제
CN113301962A (zh) * 2019-01-14 2021-08-24 先天肿瘤免疫公司 用于治疗癌症的杂环nlrp3调节剂
JP7506080B2 (ja) * 2019-01-14 2024-06-25 イネイト・テューマー・イミュニティ・インコーポレイテッド Ｎｌｒｐ３モジュレーター
WO2020168927A1 (zh) 2019-02-19 2020-08-27 四川科伦博泰生物医药股份有限公司 含氮并环化合物、其制备方法及用途
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
CN114555565B (zh) * 2019-12-13 2024-03-05 四川科伦博泰生物医药股份有限公司 含氮并环化合物、其制备方法及用途
KR20230019101A (ko) 2020-04-29 2023-02-07 상하이 린진 바이오파마 씨오., 엘티디. 벤조티아졸릴 비아릴 화합물, 제조 방법 및 용도
WO2022017408A1 (zh) * 2020-07-22 2022-01-27 中国医药研究开发中心有限公司 芳胺类衍生物及其制备方法和医药用途
KR102409345B1 (ko) * 2020-09-22 2022-06-16 가톨릭대학교 산학협력단 Nlrp3 인플라마좀 억제제 및 이의 용도
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4075343A (en) * 1976-09-13 1978-02-21 Pfizer Inc. Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof
JPS5390271A (en) * 1977-01-14 1978-08-08 Pfizer Method of producing 22aminoo44hydroxyquinoline
US4175193A (en) * 1977-01-14 1979-11-20 Pfizer Inc. 2-Amino-3-cyano-4-hydroxyquinolines
US4247699A (en) * 1979-03-14 1981-01-27 Pfizer Inc. Process for making 2-amino-4-hydroxyquinolines
GB8727737D0 (en) 1987-11-26 1987-12-31 Ici Plc Antitumour agents
JPH11209350A (ja) * 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
DK2112166T3 (en) 1998-12-23 2019-02-04 Pfizer Human monoclonal antibodies to CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
AU2002338896B2 (en) * 2001-05-21 2006-04-27 F.Hoffman-La Roche Ag Quinoline derivatives as ligands for the neuropeptide Y receptor
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US6818772B2 (en) 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
IL165871A0 (en) * 2002-06-27 2006-01-15 Schering Ag Substituted quinoline CCR5 receptor antagonists
EP2392565B1 (en) * 2003-09-26 2014-03-19 Exelixis, Inc. c-Met modulators and methods of use
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
US8686002B2 (en) * 2005-08-21 2014-04-01 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as binding partners for 5-HT5 receptors
MX2008009475A (es) 2006-01-23 2008-10-20 Amira Pharmaceuticals Inc Inhibidores triciclicos de 5-lipoxigenasa.
WO2007092854A2 (en) 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
AR065093A1 (es) * 2007-02-05 2009-05-13 Merck Frosst Canada Ltd Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
CA2713998A1 (en) 2008-01-28 2009-08-06 Janssen Pharmaceutica N.V. 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of.beta.-secretase (bace)
CN101970429B (zh) 2008-01-29 2013-05-29 詹森药业有限公司 可用作β-分泌酶(BACE)抑制剂的2-氨基喹啉衍生物
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
US8513284B2 (en) * 2009-02-13 2013-08-20 Ucb Pharma, S.A. Fused pyridine and pyrazine derivatives as kinase inhibitors
EP2504315A1 (en) 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2504330A1 (en) * 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
CA2788363A1 (en) * 2010-01-19 2011-07-28 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2012037108A1 (en) 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
EP2635279A4 (en) * 2010-11-05 2014-10-29 Glaxosmithkline Ip No 2 Ltd CHEMICAL COMPOUNDS
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
CN104736168B (zh) 2012-05-31 2018-09-21 索伦托治疗有限公司 与pd-l1结合的抗原结合蛋白
KR102243062B1 (ko) 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
ES2754269T3 (es) 2013-05-18 2020-04-16 Aduro Biotech Inc Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
JP6623353B2 (ja) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｐｄ−１抗体並びにその治療及び診断のための使用
CA2922542A1 (en) * 2013-11-22 2015-05-28 University Of Kentucky Research Foundation Arylquinoline and analog compounds and use thereof to treat cancer
ES2746805T3 (es) 2013-12-12 2020-03-06 Shanghai hengrui pharmaceutical co ltd Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
MY193765A (en) * 2015-02-16 2022-10-27 Univ Queensland Sulfonylureas and related compounds and use of same
AU2016233495B2 (en) 2015-03-13 2022-02-24 Cytomx Therapeutics, Inc Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
US20160332971A1 (en) * 2015-05-15 2016-11-17 University Of Kentucky Research Foundation Arylquinoline, arylquinolone and arylthioquinolone derivatives and use thereof to treat cancer
SI3303394T1 (sl) 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
US10329257B2 (en) * 2015-08-13 2019-06-25 The Broad Institute, Inc. Compositions and methods for treating tuberculosis
EP3337481B1 (en) * 2015-08-21 2020-11-11 The University of Kansas Quinoline-2-amine derivatives as human tlr8-selective agonists for increasing immune response
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
KR20180040706A (ko) 2015-09-01 2018-04-20 인네이트 튜머 이뮤니티, 인코포레이티드 면역억제 시토카인에 대해 증가된 면역 또는 저항성을 갖는 면역 세포 및 그의 용도
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CN108029076B (zh) 2016-02-02 2020-03-10 华为技术有限公司 确定发射功率的方法、用户设备和基站
EP3445761A1 (en) 2016-04-19 2019-02-27 Innate Tumor Immunity, Inc. Nlrp3 modulators
US10533007B2 (en) 2016-04-19 2020-01-14 Innate Tumor Immunity, Inc. NLRP3 modulators
CN106478621B (zh) * 2016-09-30 2018-12-25 遵义医学院 喹啉或喹唑啉类衍生物、制备方法及其应用
TWI808067B (zh) 2016-12-19 2023-07-11 美商雅酶股份有限公司 作為ehmt2抑制劑之胺取代的雜環化合物及其使用方法
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
WO2020168927A1 (zh) * 2019-02-19 2020-08-27 四川科伦博泰生物医药股份有限公司 含氮并环化合物、其制备方法及用途

Also Published As

Publication number Publication date
SG11202000248UA (en) 2020-02-27
KR102698385B1 (ko) 2024-08-22
ES3002968T3 (en) 2025-03-10
CN111793060B (zh) 2023-06-06
JP7159282B2 (ja) 2022-10-24
US12171756B2 (en) 2024-12-24
US20220257587A1 (en) 2022-08-18
BR112020000523A2 (pt) 2020-07-14
PE20200296A1 (es) 2020-02-06
IL271935A (en) 2020-02-27
EP3652166B1 (en) 2024-11-20
NZ761519A (en) 2023-07-28
CN110914258A (zh) 2020-03-24
TW201908304A (zh) 2019-03-01
TWI791556B (zh) 2023-02-11
CA3069524A1 (en) 2019-01-17
US20200129500A1 (en) 2020-04-30
JP2020527139A (ja) 2020-09-03
AU2018301681A1 (en) 2020-02-27
KR20200028434A (ko) 2020-03-16
US11344543B2 (en) 2022-05-31
AU2018301681B2 (en) 2022-07-14
MY201080A (en) 2024-02-03
EP3652166A1 (en) 2020-05-20
WO2019014402A1 (en) 2019-01-17
CN111793060A (zh) 2020-10-20
CO2020000227A2 (es) 2020-01-17

Similar Documents

Publication Publication Date Title
CL2020002719A1 (es) Moduladores de nlrp3
CL2020000085A1 (es) Moduladores de nlrp3.
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2018000150A1 (es) Compuestos útiles como inmunomoduladores (divisional de solicitud 201600508)
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
MX2020001360A (es) Macrociclos de diarilo como moduladores de la proteina quinasa.
UY36077A (es) Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen
CO2019013016A2 (es) Inhibidores pirazólicos de magl
ECSP16073190A (es) Ciclopropilaminas como inhibidores de lsd1
CO2017005959A2 (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
CL2018001569A1 (es) Compuestos heteroaromáticos como inhibidores de btk
CO2021014008A2 (es) Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento
CL2019002583A1 (es) Inhibidores duales de magl y faah.
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
NI201801172A (es) Nuevos compuestos para el tratamiento de enfermedades parasitarias
ECSP16074207A (es) Pirazinas moduladoras de gpr6
CL2020001093A1 (es) Proceso para preparar el benzotiofen-2-il boronato.
MX2020004871A (es) Derivados de acido cafeico y sus usos.
MX2019003311A (es) Metodos para tratamiento de cancer de ovario.
EA202090283A1 (ru) Модуляторы nlrp3
EA202092539A1 (ru) Модуляторы nlrp3